-

Avenacy Announces Launch of Bivalirudin for Injection in the U.S. Market

Company’s second product to begin shipping to wholesale partners in January

original (Photo: Business Wire)

(Photo: Business Wire)

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Bivalirudin for Injection in the United States as a therapeutic equivalent generic for Angiomax® for Injection (bivalirudin) approved by the U.S. Food and Drug Administration. Bivalirudin for Injection is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome.

Avenacy’s injectable product contains 250 mg of bivalirudin as a lyophilized powder in a single-dose vial for reconstitution. In line with Avenacy’s mission to champion patient safety and streamline patient care, Bivalirudin for Injection will feature the Company’s highly differentiated packaging and labeling to support accurate medication selection.

Avenacy will begin shipping Bivalirudin for Injection to wholesale partners this week. The Company is supported by a global network of development and FDA-approved cGMP-certified contract manufacturing partners.

Bivalirudin for Injection had U.S. sales of approximately $25 million for the twelve months ending in June 2023.1

Please see link for Full Prescribing Information.

Angiomax® is a registered trademark of Sandoz, Inc.

1Source: IQVIA

About Avenacy

Avenacy is a U.S.-based specialty pharmaceutical company focused on supplying critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved injectable products in order to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain. With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential medications.

Avenacy was launched in 2023 and is headquartered in Schaumburg, IL. For more information, please visit http://www.avenacy.com/.

Contacts

Media
FTI Consulting
Avenacy@fticonsulting.com

Industry:

Avenacy

Release Summary
Avenacy Announces Launch of Bivalirudin for Injection in the U.S. Market
Release Versions
English

Contacts

Media
FTI Consulting
Avenacy@fticonsulting.com

More News From Avenacy

Avenacy Announces Launch of Ready-to-Use Tranexamic Acid in 0.7% Sodium Chloride Injection in the U.S. Market

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Tranexamic Acid in 0.7% Sodium Chloride Injection in the United States. The product contains the same active ingredient as CYKLOKAPRON®, as approved by the U.S. Food and Drug Administration, and is indicated for use in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need...

Avenacy to Attend 2026 DCAT Week

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced that it will attend DCAT Week from March 23-26, 2026 in New York City. During DCAT Week, the Avenacy team will highlight its rapidly expanding differentiated portfolio, now comprised of twenty-six critical acute care medications and shortage products. The Company will also host meetings with potential customers and partners to discuss Avenacy’s str...

Avenacy Announces Launch of Diphenhydramine Hydrochloride Injection, USP in the U.S. Market

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced the launch of Diphenhydramine Hydrochloride Injection, USP in the United States. The product Is the generic equivalent of BENADRYL®, as approved by the U.S. Food and Drug Administration, and is indicated for the treatment of allergic reactions, including as an adjunct in anaphylaxis after acute symptoms have been controlled, for motion sickness, an...
Back to Newsroom